Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04489420 · ClinicalTrials.gov registry record · Phase 1
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
A Phase 1 study, sponsored by Celularity Incorporated.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04489420: Clinical Trial Phase 1 study, sponsored by Celularity Incorporated.
NCT04489420 is a Phase 1 study that was terminated before completion, run by Celularity Incorporated. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04489420, a Phase 1 study, was terminated before completion, sponsored by Celularity Incorporated.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study will find the maximum safe dose (MSD) or maximum tolerated dose (MTD) of CYNK-001 which are NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy for the systemic cohort (IV) (intravenous). The intratumoral cohort (IT) will not be giving lymphodepletion. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating recurrent glioblastoma multiforme.
Primary Outcome
Defined as the maximum dose safely administered intravenously or Intratumoral for the treatment of patients with GBM.
Interventions
- BIOLOGICAL CYNK001-IV
- BIOLOGICAL CYNK001-IT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2021-08-10 |
| Phase | Phase 1 |
Why NCT04489420 stopped before completion
NCT04489420 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which CYNK001-IV is the first listed.
NCT04489420 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04489420 about?
NCT04489420 is a clinical study titled "Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM". This study will find the maximum safe dose (MSD) or maximum tolerated dose (MTD) of CYNK-001 which are NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy for the systemic cohort (IV) (intravenous). The intratumoral ...
What is the current status of trial NCT04489420?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2020-10-01. Estimated completion is 2021-08-10.
What interventions are being tested in trial NCT04489420?
The interventions under investigation include: CYNK001-IV (BIOLOGICAL), CYNK001-IT (BIOLOGICAL).
Who is sponsoring clinical trial NCT04489420?
This trial is sponsored by Celularity Incorporated, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04489420's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI